公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2013 | Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients | Huang S.-P.; Lin V.C.; Lee Y.-C.; Yu C.-C.; CHAO-YUAN HUANG ; Chang T.-Y.; Lee H.-Z.; Juang S.-H.; Lu T.-L.; Bao B.-Y. | European Journal of Cancer | 19 | 20 | |
2019 | Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression | Yu C.-C.; Chen L.-C.; Chiou C.-Y.; Chang Y.-J.; Lin V.C.; CHAO-YUAN HUANG ; Lin I.-L.; Chang T.-Y.; Lu T.-L.; Lee C.-H.; Huang S.-P.; Bao B.-Y. | Cancer Cell International | 15 | 13 | |
2015 | Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer | CHAO-YUAN HUANG ; Huang S.-P.; Lin V.C.; Yu C.-C.; Chang T.-Y.; Juang S.-H.; Bao B.-Y. | Scientific Reports | 20 | 17 | |
2016 | Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survival | Bao B.-Y.; Lin V.C.; Yu C.-C.; Yin H.-L.; Chang T.-Y.; Lu T.-L.; Lee H.-Z.; Pao J.-B.; CHAO-YUAN HUANG ; Huang S.-P. | Scientific Reports | 18 | 19 | |
2015 | Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer | CHAO-YUAN HUANG ; Huang S.-P.; Lin V.C.; Yu C.-C.; Chang T.-Y.; Lu T.-L.; Chiang H.-C.; Bao B.-Y. | Scientific Reports | 28 | 23 | |
2014 | Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients | Lin V.C.; CHAO-YUAN HUANG ; Lee Y.-C.; Yu C.-C.; Chang T.-Y.; Lu T.-L.; Huang S.-P.; Bao B.-Y. | Archives of Toxicology | 12 | 11 | |
2011 | Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy | Huang S.-P.; Bao B.-Y.; Wu M.-T.; Choueiri T.K.; Goggins W.B.; CHAO-YUAN HUANG ; YEONG-SHIAU PU ; Yu C.-C.; Huang C.-H. | Prostate | 53 | 45 | |
2016 | Inherited variants in Wnt pathway genes influence outcomes of prostate cancer patients receiving androgen deprivation therapy | Geng J.-H.; Lin V.C.; Yu C.-C.; CHAO-YUAN HUANG ; Yin H.-L.; Chang T.-Y.; Lu T.-L.; Huang S.-P.; Bao B.-Y. | International Journal of Molecular Sciences | 15 | 14 | |
2012 | A modified Nordic prediction model of road traffic noise in a Taiwanese city with significant motorcycle traffic | Chang T.-Y.; Lin H.-C.; Yang W.-T.; Bao B.-Y.; CHANG-CHUAN CHAN | Science of the Total Environment | 30 | 28 | |
2013 | Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression | L?vesque E.; Huang S.-P.; Audet-Walsh E.; Lacombe L.; Bao B.-Y.; Fradet Y.; Laverdi?re I.; Rouleau M.; CHAO-YUAN HUANG ; Yu C.-C.; Caron P.; Guillemette C. | Clinical Cancer Research | 49 | 44 | |
2013 | Molecular Markers in Sex Hormone Pathway Genes Associated with the Efficacy of Androgen-Deprivation Therapy for Prostate Cancer | Yu C.-C.; Huang S.-P.; Lee Y.-C.; CHAO-YUAN HUANG ; Liu C.-C.; Hour T.-C.; Huang C.-N.; You B.-J.; Chang T.-Y.; Huang C.-H.; Bao B.-Y. | PLoS ONE | 22 | 151 | |
2021 | NRG1 genetic variant influences the efficacy of androgen-deprivation therapy in men with prostate cancer | Huang S.-P.; Chen Y.-T.; Chen L.-C.; Lee C.-H.; CHAO-YUAN HUANG ; Yu C.-C.; Lin V.C.; Lu T.-L.; Bao B.-Y. | Biomedicines | 2 | 3 | |
2020 | Polymorphism of nucleotide binding domain-like receptor protein 3 (NLRP3) increases susceptibility of total urinary arsenic to renal cell carcinoma | Chung C.-J.; Bao B.-Y.; Lin Y.-C.; Huang Y.-L.; Shiue H.-S.; Ao P.-L.; YEONG-SHIAU PU ; CHAO-YUAN HUANG ; Hsueh Y.-M. | Scientific Reports | 10 | 7 | |
2011 | Polymorphisms inside MicroRNAs and MicroRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy | Bao B.-Y.; Pao J.-B.; Huang C.-N.; YEONG-SHIAU PU ; Chang T.-Y.; Lan Y.-H.; Lu T.-L.; Lee H.-Z.; Juang S.-H.; Chen L.-M.; Hsieh C.-J.; Huang S.-P. | Clinical Cancer Research | 64 | 56 | |
2016 | Prognostic relevance of methylenetetrahydrofolate reductase polymorphisms for prostate cancer | Lin V.C.; Lu T.-L.; Yin H.-L.; Yang S.-F.; Lee Y.-C.; Liu C.-C.; CHAO-YUAN HUANG ; Yu C.-C.; Chang T.-Y.; Huang S.-P.; Bao B.-Y. | International Journal of Molecular Sciences | 7 | 4 | |
2013 | Prognostic significance of cyclin d1 polymorphisms on prostate-specific antigen recurrence after radical prostatectomy | Yu C.-C.; Lin V.C.; CHAO-YUAN HUANG ; Liu C.-C.; Wang J.-S.; Wu T.T.; YEONG-SHIAU PU ; Huang C.-H.; Huang C.-N.; Huang S.-P.; Bao B.-Y. | Annals of Surgical Oncology | 17 | 15 | |
2015 | Prognostic significance of genetic polymorphisms in disease progression and survival in prostate cancer after androgen deprivation therapy | Huang T.-Y.; Chien T.-M.; Liu C.-C.; Lee H.-Y.; Yu C.-C.; CHAO-YUAN HUANG ; Chang C.-F.; Huang C.-H.; Wu W.-J.; Bao B.-Y.; Huang S.-P. | Urological Science | 2 | 0 | |
2012 | Prognostic significance of genetic polymorphisms on prostate-specific antigen recurrence after a radical prostatectomy | Tsai Y.-F.; Bao B.-Y.; Liu C.-C.; Huang C.-N.; Yu C.-C.; Wu T.T.; CHAO-YUAN HUANG ; YEONG-SHIAU PU ; Chang C.-F.; Huang C.-H.; Wu W.-J.; Huang S.-P. | Urological Science | 0 | 0 | |
2019 | Prognostic value of CD1B in localised prostate cancer | Lee C.-H.; Chen L.-C.; Yu C.-C.; Lin W.-H.; Lin V.C.; CHAO-YUAN HUANG ; Lu T.-L.; Huang S.-P.; Bao B.-Y. | International Journal of Environmental Research and Public Health | 14 | 11 | |
2016 | Prognostic value of prostaglandin-endoperoxide synthase 2 polymorphisms in prostate cancer recurrence after radical prostatectomy | Lee C.-H.; Pao J.-B.; Lu T.-L.; Lee H.-Z.; Lee Y.-C.; Liu C.-C.; CHAO-YUAN HUANG ; Lin V.C.; Yu C.-C.; Yin H.-L.; Huang S.-P.; Bao B.-Y. | International Journal of Medical Sciences | 5 | 2 |